New agents in development for the management of obesity

International Journal of Clinical Practice

Volumn 61, Issue 12, 2007, Pages 2103-2112

  Vincent, R P ^a   Le Roux, C W ^a,b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,4 BENZODIOXAN 2 CARBOXYLIC ACID; AC 162352; AMIODARONE; ANTIOBESITY AGENT; APD 356; ATL 962; ATOMOXETINE; AZ 40140; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BVT 933; CILIARY NEUROTROPHIC FACTOR; CYCLOSPORIN; ECOPIPAM; EXENDIN 4; GASTROINTESTINAL HORMONE; GHRELIN; GI 181771; GLUCAGON LIKE PEPTIDE 1; HMR 1426; HORMONE RECEPTOR STIMULATING AGENT; LEPTIN; MANIFAXINE; MLN 4760; NOX B 11 2; OLIGONUCLEOTIDE; ORG 12962; OXYNTOMODULIN; PEPTIDE YY; PEPTIDE YY 3-36; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PLACEBO; PNU 22394; PRAMLINTIDE; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RIMONABANT; SEROTONIN AGONIST; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ANXIETY; BODY MASS; CAUSE OF DEATH; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG WITHDRAWAL; ENERGY METABOLISM; EPIDEMIC; FECES INCONTINENCE; FOOD INTAKE; HEALTH CARE COST; HEART ARRHYTHMIA; HOMEOSTASIS; HUMAN; HYPERTENSION; INSOMNIA; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MENTAL DISEASE; NAUSEA; NEUROENDOCRINE SYSTEM; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; STEATORRHEA; SUICIDE; SUICIDE ATTEMPT; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; DRUGS, INVESTIGATIONAL; HOMEOSTASIS; HUMANS; NEUROSECRETORY SYSTEMS; OBESITY;

EID: 35948946835     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01558.x     Document Type: Review

References (92)

1. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000 894 : 1 253.
2. International Diabetes Federation. Diabetes Atlas. Executive Summary, 2nd ed. Belgium : Imprimerie L Vanmelle SA, Gent/Mariakerke, 2003.
3. Visscher TL, Seidell JC. The public health impact of obesity. Annu Rev Public Health 2001 22 : 355 75.
4. Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998 97 : 2099 100.
5. Ferrannini E, Natali A, Capaldo B et al. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 1997 30 : 1144 9.
6. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. National Institutes of Health. Obes Res 1998 6 : 51S 209S.
7. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003 289 : 76 9.
8. Gami AS, Caples SM, Somers VK. Obesity and obstructive sleep apnoea. Endocrinol Metab Clin North Am 2003 32 : 869 94.
9. Huda MSB, Wilding JPH, Pinkney JH. Gut peptides and the regulation of appetite. Obes Rev 2006 7 : 163 82.
10. NICE Clinical Guideline 43. Obesity: Guidance on the Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children. National Institute for Health and Clinical Excellence, 2006. http://guidance.nice.org.uk/CG43 (accessed 1 June 2007).
11. Maggard MA, Shugarman LR, Suttorp M et al. Meta analysis: surgical treatment of obesity. Ann Intern Med 2005 142 : 547 59.
12. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004 89 : 2608 615.
13. Avenell A, Broom J, Brown TJ et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004 8 : 1 182.
14. Goldstein DJ. Beneficial effects of modest weight loss. Int J Obes Relat Metab Disord 1992 16 : 397 415.
15. Morton GJ, Cummings DE, Baskin DG et al. Central nervous system control of food intake and body weight. Nature 2006 443 : 289 95.
16. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004 116 : 337 50.
17. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995 332 : 621 8.
18. Schwartz MW, Woods SC, Seeley RJ et al. Is the energy homeostasis system inherently biased toward weight gain? Diabetes 2003 52 : 232 8.
19. West DB, Fey D, Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 1984 246 : 776 87.
20. Cummings DE, Foster-Schubert KE, Overduin J. Ghrelin and energy balance: focus on current controversies. Curr Drug Targets 2005 6 : 153 69.
21. Shearman LP, Wang SP, Helmling S et al. Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 2006 147 : 1517 26.
22. le Roux CW, Patterson M, Vincent RP et al. Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab 2005 90 : 1068 71.
23. Shearman LP, Wang SP, Helmling S et al. Ghrelin neutralization by ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 2006 147 : 1517 26.
24. Degen L, Oesch S, Casanova M et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005 129 : 1430 6.
25. Batterham RL, Cowley MA, Small CJ et al. Gut hormone PYY (3-36) physiologically inhibits food intake. Nature 2002 418 : 650 4.
26. Batterham RL, Cohen MA, Ellis SM et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003 349 : 941 8.
27. Halford JC. Obesity drugs in clinical development. Curr Opin Investig Drugs 2006 7 : 312 8.
28. Cummings D, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007 117 : 13 23.
29. Henry RR, Ratner RE, Stonehouse AH et al. Exenatide Maintained Glycemic Control with Associated Weight Reduction over 2 years in Patients with Type 2 Diabetes. Washington, DC : American Diabetes Association 66th Scientific Sessions, 2006 (Abstract 485P).
30. Cohen MA, Ellis SM, Le Roux CW et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003 88 : 4696 701.
31. Wynne K, Park AJ, Small CJ et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005 54 : 2390 5.
32. Mancini MC, Halpern A. Investigational therapies in the treatment of obesity. Expert Opin Investig Drugs 2006 15 : 897 915.
33. Das SK, Chakrabarti R. Anti-obesity therapy: imaging drugs and targets. Curr Med Chem 2006 13 : 1429 60.
34. Padwal RS, Li SK, Lau DCW. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003 4 : CD004094.
35. Torgerson JS, Hauptman J, Boldrin MN et al. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 2004 27 : 155 61.
36. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity. Int J Obes Relat Metab Disord 2003 27 : 1437 46.
37. McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of type 2 diabetic patients treated with metformin. Diabetes Care 2003 26 : 125 31.
38. Wadden TA, Berkowitz RI, Womble LG et al. Randomised trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005 353 : 2111 20.
39. Foater-Schubert KE, Cummings DE. Emerging therapeutic strategies for obesity. Endocr Rev 2006 27 : 779 93.
40. Pagotto U, Marsicano G, Cota D et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006 27 : 73 100.
41. Despres JP, Golay A, Sjostrom L. Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in over weight patients with dyslipidemia. N Engl J Med 2005 353 : 2121 34.
42. Van Gaal LF, Rissanen AM, Scheen AJ et al. RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 365 : 1389 97.
43. Scheen AJ, Finer N, Hollander P et al. RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes. Lancet 2006 368 : 1160 72.
44. Pi-Sunyer FX, Aronne LJ, Heshmati HM et al. RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 2006 295 : 761 75.
45. Wierzbicki AS. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Int J Clin Pract 2006 60 : 1697 706.
46. Weibel EK, Hadvary P, Hochuli E et al. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini, I: producing organism, fermentation, isolation and biological activity. J Antibiot (Tokyo) 1987 40 : 1081 5.
47. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0467 (tetrahydrolipstatin). Am J Clin Nutr 1992 55 : 309S 13S.
48. McNeely W, Benfield P. Orlistat. Drugs 1998 56 : 241 9.
49. Zhi J, Moore R, Kanitra L et al. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine and simvastatin) in healthy subjects. J Clin Pharmacol 2003 43 : 428 35.
50. Zhi J, Moore R, Kanitra L et al. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in health subjects. J Clin Pharmacol 2002 42 : 1011 9.
51. MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother 2003 37 : 510 2.
52. McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998 56 : 1093 124.
53. Lean ME. How does sibutramine work? Int J Obes Relat Metab Disord 2001 25 : S8 11.
54. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 2002 166 : 1307 8.
55. Mechoulam R. Cannabinoids as Therapeutic Agents. Boca Raton, FL : CRC Press, 1986.
56. Rinaldi-Carmona M, Barth F, Heaulme M et al. Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 1995 56 : 1941 47.
57. Carai MAM, Colombo G, Gessa GL. Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci 2005 77 : 2339 50.
58. Thomas Boyd S, Fremming BA. Rimonabant: a selective CB1 antagonist. Ann Pharmacother 2005 39 : 684 90.
59. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007 369 : 71 7.
60. Gadde KM, Yonish GM, Wagner HR 2nd. et al. Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial. Int J Obes 2006 30 : 1138 42.
61. Heisler LK, Jobst EE, Sutton GM et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 2006 51 : 239 49.
62. Sargent PA, Sharpley AL, Williams C et al. 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology (Berl) 1997 133 : 309 12.
63. Smith S, Prosser W, Donahue D et al. APD356, an Orally-active Selective 5-HT2C Agonist, Reduces Body Weight in Obese Adult Men and Women. Washington, DC : American Diabetes Association 66th Scientific Sessions, 2006 (Abstract 344-OR).
64. Soll RM, Dinger MC, Lundell I et al. Novel analogues of neuropeptide Y with a preference for the Y1-receptor. Eur J Biochem 2001 268 : 2828 37.
65. Feletou M, Galizzi JP, Levens NR. NPY receptors as drug targets for the central regulation of body weight. CNS Neurol Disord Drug Targets 2006 5 : 263 74.
66. Ludwig DS, Tritos NA, Mastaitis JW et al. Melanin concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest 2001 107 : 379 86.
67. Shimada M, Tritos NA, Lowell BB et al. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998 396 : 670 4.
68. Pissios P, Bradley RL, Maratos-Flier E. Expanding the scales: the multiple roles of MCH in regulating energy balance and other biological functions. Endocr Rev 2006 27 : 606 20.
69. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996 46 : 1244 9.
70. Jobst EE, Enriori PJ, Sinnayah P et al. Hypothalamic regulatory pathways and potential obesity treatment targets. Endocrine 2006 29 : 33 48.
71. Anderson KD, Lambert PD, Corcoran TL et al. Activation of the hypothalamic arcuate nucleus predicts the anorectic actions of ciliary neurotrophic factor and leptin in intact and gold thioglucose-lesioned mice. J Neuroendocrinol 2003 15 : 649 60.
72. Marsh DJ, Hollopeter G, Huszar D et al. Response of melanocortin-4- deficient mice to anorectic and orexigenic peptides. Nat Genet 1999 21 : 119 22.
73. Gloaguen I, Costa P, Demartis A et al. Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc Natl Acad Sci U S A 1997 94 : 6456 61.
74. Kokoeva MV, Yin H, Flier JS. Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science 2005 310 : 679 83.
75. Ettinger MP, Littlejohn TW, Schwartz SL et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 2003 289 : 1826 32.
76. Fliedner S, Schulz C, Lehnert H. Brain uptake of intranasally applied radioiodinated leptin in Wistar rats. Endocrinology 2006 147 : 2088 94.
77. Tartaglia LA, Dembski M, Weng X et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995 83 : 1263 71.
78. Peelman F, Couturier C, Dam J et al. Techniques: new pharmacological perspectives for the leptin receptor. Trends Pharmacol Sci 2006 27 : 218 25.
79. Bjorbaek C, Elmquist JK, Frantz JD et al. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1998 1 : 619 25.
80. Wang MY, Orci L, Ravazzola M et al. Fat storage in adipocytes requires inactivation of leptin's paracrine activity: implications for treatment of human obesity. Proc Natl Acad Sci U S A 2005 102 : 18011 6.
81. Mori H, Hanada R, Hanada T et al. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 2004 10 : 739 43.
82. Zhang Y, Proenca R, Maffei M et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994 372 : 425 31.
83. Farooqi I, Jebb S, Langmack G et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999 341 : 879 84.
84. Heymsfield SB, Greenberg AS, Fujioka K et al. Recombinant leptin for weight loss in obese and lean adults. JAMA 1999 282 : 1568 75.
85. Boozer CN, Leibel RL, Love RJ et al. Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats. Metabolism 2001 50 : 889 93.
86. Huszar D, Lynch CA, Fairchild-Huntress V et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997 88 : 131 41.
87. Vaisse C, Clement K, Guy-Grand B et al. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 1998 20 : 113 4.
88. Vaisse C, Clement K, Durand E et al. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000 106 : 253 62.
89. Fan W, Boston B, Kesterson R et al. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997 385 : 165 8.
90. Baskin DG. Single-minded view of melanocortin signaling in energy homeostasis. Endocrinology 2006 147 : 4539 41.
91. Michaud JL, Boucher F, Melnyk A et al. Sim1 haploinsufficiency causes hyperphagia, obesity and reduction of the paraventricular nucleus of the hypothalamus. Hum Mol Genet 2001 10 : 1465 73.
92. Holder JL, Butte NF, Zinn AR. Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. Hum Mol Genet 2000 9 : 101 8.